BRCA OncoKitDx

Background on BRCA1 and BRCA2

Mutations in the BRCA1 and BRCA2 genes are among the most significant genetic factors associated with hereditary breast and ovarian cancer. These genes encode proteins involved in DNA repair through homologous recombination, a critical pathway for maintaining genomic stability. Loss of function in either gene leads to increased genomic instability and a higher risk of tumor development.

Breast cancer is one of the most common malignancies worldwide, and a subset of cases is linked to inherited BRCA mutations. In addition to germline variants, somatic alterations in BRCA1 and BRCA2 are also observed in tumor tissues and contribute to cancer progression and treatment response. Detection of both variant types is therefore essential for comprehensive research into cancer genetics, tumor biology, and therapeutic targeting.

Accurate identification of BRCA variants supports studies on cancer susceptibility, genotype-phenotype correlations, and mechanisms of DNA repair deficiency. It also plays a role in research on targeted therapies, including PARP inhibitors, which exploit defects in DNA repair pathways.

Kit Description

The BRCA OncoKitDx™ is designed for the detection of both germline and somatic variants in BRCA1 and BRCA2 using Next-Generation Sequencing. The assay combines multiplex PCR with NGS technology to enable high-throughput analysis of relevant genomic regions.

The workflow allows simultaneous analysis of multiple targets, covering coding regions, splice junctions, and small insertions and deletions. This comprehensive approach supports detailed characterization of BRCA variants within a single assay.

The kit is compatible with genomic DNA extracted from peripheral blood as well as formalin-fixed, paraffin-embedded (FFPE) tumor tissue. This flexibility enables comparative analysis of germline and tumor-derived variants within the same experimental framework.

Workflow and Integration

The assay is designed for efficient integration into standard molecular biology workflows. With a low DNA input requirement, the protocol supports sample-limited applications while maintaining consistent sequencing performance.

The combination of multiplex PCR and NGS enables streamlined processing of multiple samples, reducing hands-on time and supporting high-throughput analysis. The kit is compatible with commonly used sequencing platforms, facilitating adoption in laboratories with existing NGS infrastructure.

Research Applications

Detection of BRCA1 and BRCA2 variants is central to research on hereditary cancer syndromes and tumor genetics. Identification of germline mutations enables studies on inherited cancer risk, while detection of somatic variants supports investigation of tumor evolution and heterogeneity.

The assay supports research into DNA repair mechanisms, genomic instability, and therapeutic response. In particular, BRCA mutation status is a key factor in studies evaluating sensitivity to targeted therapies, such as PARP inhibitors, and in understanding mechanisms of resistance.

In addition, comprehensive BRCA analysis contributes to biomarker discovery and the development of personalized medicine approaches in oncology research.

Summary

The BRCA OncoKitDx™ provides a comprehensive, NGS-based solution for the detection of germline and somatic variants in BRCA1 and BRCA2. Its multiplex PCR design, broad genomic coverage, and compatibility with blood and tumor samples enable detailed and reproducible variant analysis.

Optimized for integration into molecular workflows, the kit supports high-throughput sequencing while maintaining analytical accuracy. By enabling reliable identification of clinically relevant BRCA variants, the BRCA OncoKitDx™ supports research into cancer genetics, tumor biology, and targeted therapeutic strategies.